GlaxoSmithKline places its shingles vaccine ... shot in all territories other than BioNTech's home market of Germany, Turkey and certain other developing countries. "Adults aged 50 years and ...
Visitors to Columbia’s antique shops, river trail and Turkey Hill Experience will no longer have to leave town to find a ...
Astellas also has rights to the drug in Japan – where it also approved and on sale – as well as Turkey, Russia ... has provided an opportunity for GSK and Akebia to beat FibroGen and AZ ...
Turkey has begun exporting around 15,000 tonnes of eggs to the ... The Government of Canada has secured an initial supply of 500,000 doses of GSK's bird flu vaccine to protect individuals most at risk ...
It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...
The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...
LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...
It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...
Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...
GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results